Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jun 1;99(11):2655–2663. doi: 10.1172/JCI119454

Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

J Petäjä 1, J A Fernández 1, A Gruber 1, J H Griffin 1
PMCID: PMC508111  PMID: 9169495

Abstract

Interactions between standard heparin and the physiological anticoagulant plasma protein, activated protein C (APC) were studied. The ability of heparin to prolong the activated partial thromboplastin time and the factor Xa- one-stage clotting time of normal plasma was markedly enhanced by addition of purified APC to the assays. Experiments using purified clotting factors showed that heparin enhanced by fourfold the phospholipid-dependent inactivation of factor V by APC. In contrast to factor V, there was no effect of heparin on inactivation of thrombin-activated factor Va by APC. Based on SDS-PAGE analysis, heparin enhanced the rate of proteolysis of factor V but not factor Va by APC. Coagulation assays using immunodepleted plasmas showed that the enhancement of heparin action by APC was independent of antithrombin III, heparin cofactor II, and protein S. Experiments using purified proteins showed that heparin did not inhibit factor V activation by thrombin. In summary, heparin and APC showed significant anticoagulant synergy in plasma due to three mechanisms that simultaneously decreased thrombin generation by the prothrombinase complex. These mechanisms include: first, heparin enhancement of antithrombin III-dependent inhibition of factor V activation by thrombin; second, the inactivation of membrane-bound FVa by APC; and third, the proteolytic inactivation of membrane-bound factor V by APC, which is enhanced by heparin.

Full Text

The Full Text of this article is available as a PDF (240.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrow R. T., Healey J. F., Lollar P. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex. J Biol Chem. 1994 Jan 7;269(1):593–598. [PubMed] [Google Scholar]
  2. Barrow R. T., Parker E. T., Krishnaswamy S., Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem. 1994 Oct 28;269(43):26796–26800. [PubMed] [Google Scholar]
  3. Baruch D., Lindhout T., Wagenvoord R., Hemker H. C. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III. Haemostasis. 1986;16(2):71–81. doi: 10.1159/000215276. [DOI] [PubMed] [Google Scholar]
  4. Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. doi: 10.1038/369064a0. [DOI] [PubMed] [Google Scholar]
  5. Branson H. E., Katz J., Marble R., Griffin J. H. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983 Nov 19;2(8360):1165–1168. doi: 10.1016/s0140-6736(83)91216-3. [DOI] [PubMed] [Google Scholar]
  6. Buchanan M. R., Boneu B., Ofosu F., Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood. 1985 Jan;65(1):198–201. [PubMed] [Google Scholar]
  7. Béguin S., Lindhout T., Hemker H. C. The mode of action of heparin in plasma. Thromb Haemost. 1988 Dec 22;60(3):457–462. [PubMed] [Google Scholar]
  8. Dahlbäck B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1004–1008. doi: 10.1073/pnas.90.3.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res. 1995 Jan 1;77(1):1–43. doi: 10.1016/0049-3848(94)00138-4. [DOI] [PubMed] [Google Scholar]
  10. Dollery C. M., Sullivan I. D., Bauraind O., Bull C., Milla P. J. Thrombosis and embolism in long-term central venous access for parenteral nutrition. Lancet. 1994 Oct 15;344(8929):1043–1045. doi: 10.1016/s0140-6736(94)91707-8. [DOI] [PubMed] [Google Scholar]
  11. Dreyfus M., Magny J. F., Bridey F., Schwarz H. P., Planché C., Dehan M., Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med. 1991 Nov 28;325(22):1565–1568. doi: 10.1056/NEJM199111283252207. [DOI] [PubMed] [Google Scholar]
  12. Esmon C. T. The protein C anticoagulant pathway. Arterioscler Thromb. 1992 Feb;12(2):135–145. doi: 10.1161/01.atv.12.2.135. [DOI] [PubMed] [Google Scholar]
  13. España F., Berrettini M., Griffin J. H. Purification and characterization of plasma protein C inhibitor. Thromb Res. 1989 Aug 1;55(3):369–384. doi: 10.1016/0049-3848(89)90069-8. [DOI] [PubMed] [Google Scholar]
  14. Fay P. J., Smudzin T. M., Walker F. J. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem. 1991 Oct 25;266(30):20139–20145. [PubMed] [Google Scholar]
  15. Foster W. B., Nesheim M. E., Mann K. G. The factor Xa-catalyzed activation of factor V. J Biol Chem. 1983 Nov 25;258(22):13970–13977. [PubMed] [Google Scholar]
  16. Fulcher C. A., Gardiner J. E., Griffin J. H., Zimmerman T. S. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood. 1984 Feb;63(2):486–489. [PubMed] [Google Scholar]
  17. Greengard J. S., Sun X., Xu X., Fernandez J. A., Griffin J. H., Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994 May 28;343(8909):1361–1362. doi: 10.1016/s0140-6736(94)92497-x. [DOI] [PubMed] [Google Scholar]
  18. Griffin J. H., Evatt B., Wideman C., Fernández J. A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993 Oct 1;82(7):1989–1993. [PubMed] [Google Scholar]
  19. Griffin J. H., Evatt B., Zimmerman T. S., Kleiss A. J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981 Nov;68(5):1370–1373. doi: 10.1172/JCI110385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gruber A., Griffin J. H. Direct detection of activated protein C in blood from human subjects. Blood. 1992 May 1;79(9):2340–2348. [PubMed] [Google Scholar]
  21. Gruber A., Harker L. A., Hanson S. R., Kelly A. B., Griffin J. H. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation. 1991 Dec;84(6):2454–2462. doi: 10.1161/01.cir.84.6.2454. [DOI] [PubMed] [Google Scholar]
  22. Gruber A., Pál A., Kiss R. G., Sas G., Griffin J. H. Generation of activated protein C during thrombolysis. Lancet. 1993 Nov 20;342(8882):1275–1276. doi: 10.1016/0140-6736(93)92364-y. [DOI] [PubMed] [Google Scholar]
  23. Hackeng T. M., van 't Veer C., Meijers J. C., Bouma B. N. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem. 1994 Aug 19;269(33):21051–21058. [PubMed] [Google Scholar]
  24. Hanson S. R., Griffin J. H., Harker L. A., Kelly A. B., Esmon C. T., Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 1993 Oct;92(4):2003–2012. doi: 10.1172/JCI116795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Heeb M. J., Kojima Y., Greengard J. S., Griffin J. H. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood. 1995 Jun 15;85(12):3405–3411. [PubMed] [Google Scholar]
  26. Higgins D. L., Mann K. G. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem. 1983 May 25;258(10):6503–6508. [PubMed] [Google Scholar]
  27. Hirahara K., Etoh Y., Matsuishi T., Suzuki N., Kurata M. Synergistic effect of antithrombin III, activated protein C and heparin on the inhibition of the tissue thromboplastin-mediated coagulation. Chem Pharm Bull (Tokyo) 1989 Mar;37(3):692–696. doi: 10.1248/cpb.37.692. [DOI] [PubMed] [Google Scholar]
  28. Hirsh J., Raschke R., Warkentin T. E., Dalen J. E., Deykin D., Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995 Oct;108(4 Suppl):258S–275S. doi: 10.1378/chest.108.4_supplement.258s. [DOI] [PubMed] [Google Scholar]
  29. Kalafatis M., Bertina R. M., Rand M. D., Mann K. G. Characterization of the molecular defect in factor VR506Q. J Biol Chem. 1995 Feb 24;270(8):4053–4057. doi: 10.1074/jbc.270.8.4053. [DOI] [PubMed] [Google Scholar]
  30. Kalafatis M., Haley P. E., Lu D., Bertina R. M., Long G. L., Mann K. G. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. Blood. 1996 Jun 1;87(11):4695–4707. [PubMed] [Google Scholar]
  31. Kalafatis M., Rand M. D., Mann K. G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994 Dec 16;269(50):31869–31880. [PubMed] [Google Scholar]
  32. Kazama Y., Koide T. Modulation of protein C inhibitor activity by histidine-rich glycoprotein and platelet factor 4: role of zinc and calcium ions in the heparin-neutralizing ability of histidine-rich glycoprotein. Thromb Haemost. 1992 Jan 23;67(1):50–55. [PubMed] [Google Scholar]
  33. Keller F. G., Ortel T. L., Quinn-Allen M. A., Kane W. H. Thrombin-catalyzed activation of recombinant human factor V. Biochemistry. 1995 Mar 28;34(12):4118–4124. doi: 10.1021/bi00012a030. [DOI] [PubMed] [Google Scholar]
  34. Koster T., Rosendaal F. R., de Ronde H., Briët E., Vandenbroucke J. P., Bertina R. M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993 Dec 18;342(8886-8887):1503–1506. doi: 10.1016/s0140-6736(05)80081-9. [DOI] [PubMed] [Google Scholar]
  35. Krishnaswamy S., Williams E. B., Mann K. G. The binding of activated protein C to factors V and Va. J Biol Chem. 1986 Jul 25;261(21):9684–9693. [PubMed] [Google Scholar]
  36. Lu D., Kalafatis M., Mann K. G., Long G. L. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood. 1996 Jun 1;87(11):4708–4717. [PubMed] [Google Scholar]
  37. Marlar R. A., Griffin J. H. Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest. 1980 Nov;66(5):1186–1189. doi: 10.1172/JCI109952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Marlar R. A., Kleiss A. J., Griffin J. H. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 1982 May;59(5):1067–1072. [PubMed] [Google Scholar]
  39. Monkovic D. D., Tracy P. B. Activation of human factor V by factor Xa and thrombin. Biochemistry. 1990 Feb 6;29(5):1118–1128. doi: 10.1021/bi00457a004. [DOI] [PubMed] [Google Scholar]
  40. Nesheim M. E., Canfield W. M., Kisiel W., Mann K. G. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem. 1982 Feb 10;257(3):1443–1447. [PubMed] [Google Scholar]
  41. Ofosu F. A., Blajchman M. A., Modi G., Cerskus A. L., Hirsh J. Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin. 1981 Aug 15-Sep 1Thromb Res. 23(4-5):331–345. doi: 10.1016/0049-3848(81)90194-8. [DOI] [PubMed] [Google Scholar]
  42. Ofosu F. A., Hirsh J., Esmon C. T., Modi G. J., Smith L. M., Anvari N., Buchanan M. R., Fenton J. W., 2nd, Blajchman M. A. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J. 1989 Jan 1;257(1):143–150. doi: 10.1042/bj2570143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Ofosu F. A., Lormeau J. C., Craven S., Dewar L., Anvari N. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Thromb Haemost. 1994 Dec;72(6):862–868. [PubMed] [Google Scholar]
  44. Ofosu F. A., Sie P., Modi G. J., Fernandez F., Buchanan M. R., Blajchman M. A., Boneu B., Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J. 1987 Apr 15;243(2):579–588. doi: 10.1042/bj2430579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Petăjă J., Peltola K., Sairanen H., Leijala M., Kekomäki R., Vahtera E., Siimes M. A. Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations. J Thorac Cardiovasc Surg. 1996 Sep;112(3):665–671. doi: 10.1016/S0022-5223(96)70050-8. [DOI] [PubMed] [Google Scholar]
  46. Pieters J., Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood. 1988 Dec;72(6):2048–2052. [PubMed] [Google Scholar]
  47. Regan L. M., O'Brien L. M., Beattie T. L., Sudhakar K., Walker F. J., Fay P. J. Activated protein C-catalyzed proteolysis of factor VIIIa alters its interactions within factor Xase. J Biol Chem. 1996 Feb 23;271(8):3982–3987. doi: 10.1074/jbc.271.8.3982. [DOI] [PubMed] [Google Scholar]
  48. Sakamoto T., Ogawa H., Yasue H., Oda Y., Kitajima S., Tsumoto K., Mizokami H. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis. Circulation. 1994 Jul;90(1):427–432. doi: 10.1161/01.cir.90.1.427. [DOI] [PubMed] [Google Scholar]
  49. Schoen P., Lindhout T. Flow and the inhibition of prothrombinase by antithrombin III and heparin. Blood. 1991 Jul 1;78(1):118–124. [PubMed] [Google Scholar]
  50. Schramm W., Spannagl M., Bauer K. A., Rosenberg R. D., Birkner B., Linnau Y., Schwarz H. P. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol. 1993 Jun;129(6):753–756. [PubMed] [Google Scholar]
  51. Sobel M., McNeill P. M., Carlson P. L., Kermode J. C., Adelman B., Conroy R., Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest. 1991 May;87(5):1787–1793. doi: 10.1172/JCI115198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Solymoss S., Tucker M. M., Tracy P. B. Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem. 1988 Oct 15;263(29):14884–14890. [PubMed] [Google Scholar]
  53. Sun X., Evatt B., Griffin J. H. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood. 1994 Jun 1;83(11):3120–3125. [PubMed] [Google Scholar]
  54. Suzuki K., Nishioka J., Kusumoto H., Hashimoto S. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem. 1984 Jan;95(1):187–195. doi: 10.1093/oxfordjournals.jbchem.a134583. [DOI] [PubMed] [Google Scholar]
  55. Suzuki K., Stenflo J., Dahlbäck B., Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem. 1983 Feb 10;258(3):1914–1920. [PubMed] [Google Scholar]
  56. Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994 Feb 24;330(8):517–522. doi: 10.1056/NEJM199402243300801. [DOI] [PubMed] [Google Scholar]
  57. Voorberg J., Roelse J., Koopman R., Büller H., Berends F., ten Cate J. W., Mertens K., van Mourik J. A. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994 Jun 18;343(8912):1535–1536. doi: 10.1016/s0140-6736(94)92939-4. [DOI] [PubMed] [Google Scholar]
  58. Walker F. J. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem. 1980 Jun 25;255(12):5521–5524. [PubMed] [Google Scholar]
  59. Woodman R. C., Harker L. A. Bleeding complications associated with cardiopulmonary bypass. Blood. 1990 Nov 1;76(9):1680–1697. [PubMed] [Google Scholar]
  60. Yang X. J., Blajchman M. A., Craven S., Smith L. M., Anvari N., Ofosu F. A. Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl. Biochem J. 1990 Dec 1;272(2):399–406. doi: 10.1042/bj2720399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. van Putten J., van de Ruit M., Beunis M., Hemker H. C. Interindividual variation in relationships between plasma heparin concentration and the results of five heparin assays. Clin Chim Acta. 1982 Jul 1;122(2):261–270. doi: 10.1016/0009-8981(82)90285-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES